Lisata Therapeutics (NASDAQ:LSTA) Posts Quarterly Earnings Results, Beats Expectations By $0.41 EPS

Lisata Therapeutics (NASDAQ:LSTA) issued its quarterly earnings data on Thursday. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.41, FiscalAI reports. The firm had revenue of $0.10 million for the quarter.

Lisata Therapeutics Stock Performance

Shares of NASDAQ LSTA opened at $5.03 on Friday. The firm has a market cap of $44.36 million, a PE ratio of -2.63 and a beta of 1.28. The company has a fifty day moving average price of $3.93 and a 200 day moving average price of $2.83. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $5.07.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LSTA. Cerity Partners LLC bought a new stake in Lisata Therapeutics during the second quarter worth about $32,000. CIBC Bancorp USA Inc. bought a new stake in shares of Lisata Therapeutics in the 3rd quarter valued at about $37,000. Finally, Renaissance Technologies LLC raised its stake in Lisata Therapeutics by 6.1% in the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after buying an additional 7,093 shares during the period. Institutional investors and hedge funds own 8.94% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Brookline Capital Acquisition cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Lisata Therapeutics has an average rating of “Hold” and a consensus target price of $23.50.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.